Title Collection Author Date
The Problem With Buy and Hold Fund Research & Insights David Brenchley 25/04/19
GlaxoSmithKline Still Undervalued, say Analysts Equity Research & Insights Damien Conover 08/02/19
Can Healthcare Stocks Continue their 2018 Rally? Equity Research & Insights David Brenchley 30/01/19
Woodford-Backed Prothena Loses 70% Equity Research & Insights David Brenchley 24/04/18
Takeda Takeover Bid for Shire: Analyst View Equity Research & Insights Karen Andersen, CFA 29/03/18
Novartis Deal Will Strengthen Glaxo's Dividend say Analysts Equity Research & Insights Damien Conover, CFA 28/03/18
Glaxo Dividend Cut Unlikely say Analysts Equity Research & Insights Damien Conover 26/10/17
Revealed: The Funds Hit by AstraZeneca Slump Fund Research & Insights Karen Kwok 27/07/17
AstraZeneca Falls 16% as Drug Trial Falters Equity Research & Insights Emma Wall 27/07/17
Biotech Trusts Trade at Discount Investment Trust Research & Insights Karen Kwok 26/05/17
Market Outlook: Healthcare Stocks Equity Research & Insights Damien Conover, CFA 13/04/17
US Election is the Biggest Challenge to Healthcare Stocks Equity Research & Insights Karen Kwok 14/04/16
AstraZeneca Fairly Valued after Solid Q3 Equity Research & Insights Damien Conover, CFA 10/11/15
4 Pharma Stocks Best Placed in Cancer Market Equity Research & Insights Stefan Quenneville, CFA 30/03/15
Is Glaxo's Dividend at Risk? Equity Research & Insights Damien Conover, CFA 05/02/15
AstraZeneca now Overvalued Equity Research & Insights Emma Wall 17/01/14
AstraZeneca is "Undervalued" Say Analysts Equity Research & Insights Damien Conover, CFA 08/08/13
Page   1 of 1
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures